Literature DB >> 3079643

Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL.

M Alvarez de Mon, J Casas, R Laguna, M L Toribio, M O de Landázuri, A Durántez.   

Abstract

T cells from patients with B cell chronic lymphocytic leukemia (B-CLL) exhibit defective natural killer (NK) activity. In this study, we have analyzed the cytotoxic-inducer effects of gamma interferon (gamma-IFN) and supernatants containing interleukin 2 (IL 2 sup). T cells from patients with B-CLL were incubated with gamma-IFN or IL 2 sup. gamma-IFN did not modulate the very low or undetectable levels of NK activity present in the T cell population. However, the IL 2 sup induced a potent cellular cytotoxicity against NK-sensitive and NK-resistant tumoral target cells. This cytotoxic inducer effect (a) was present in lectin-free IL 2 sup and in a 15,000- to 20,000-dalton molecular weight fraction obtained by gel filtration chromatography of this supernatant; (b) was directed against NK-sensitive and NK-resistant target cells; (c) was not correlated with the basal levels of NK activity; and (d) was not associated with a development or augmentation of the proportion of lymphocytes with classic NK cell phenotype. Taken together, these results demonstrate that unstimulated T cells from B-CLL patients, incubated briefly (18 hours) with IL 2 sup but not gamma-IFN, have strong NK-like cytotoxicity, despite the lack of classic NK activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2.

Authors:  L Manzano; M Alvarez-Mon; L Abreu; J Antonio Vargas; E de la Morena; F Corugedo; A Duràntez
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

2.  Cytotoxic lymphocytes in B-cell chronic lymphocytic leukemia. A flow cytometric study of peripheral blood, lymph nodes and bone marrow.

Authors:  L W Terstappen; B G de Grooth; I Segers-Nolten; J Greve
Journal:  Blut       Date:  1990-02

3.  Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy.

Authors:  G Pawelec; H Schmidt; E Schneider; H J Bühring; G Ehninger
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients.

Authors:  L Manzano; M Alvarez-Mon; J A Vargas; J A Girón; L Abreu; A Fernández-Corugedo; L I Román; F Albarran; A Durántez
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

5.  Interferon beta enhances the natural killer activity of patients with bladder carcinoma.

Authors:  L Moltó; J Carballido; L Manzano; C Olivier; P Lapeña; M Alvarez-Mon
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

6.  Functional defect of T cells in autoimmune gastritis.

Authors:  J A Vargas; M Alvarez-Mon; L Manzano; A Albillos; A Fernandez-Corugedo; F Albarrán; A Durántez
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

7.  Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.

Authors:  L Molto; M Alvarez-Mon; J Carballido; L Manzano; C Guillen; A Prieto; C Olivier; M Rodriguez-Zapata
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.